Drug Trial Radar · NCT06634589
A Study to Investigate Safety and Effectiveness of Tacabrutideg (BGB-16673) in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell Malignancies
Last checked: Nov 20, 2026Latest source record: Sep 11, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
80
Planned (sponsor's estimate)
Start
Nov 27, 2024
Primary completion
Dec 2, 2028
Study completion Dec 2, 2029
Sponsor
- Lead sponsor
- BeOne MedicinesBeOne Medicines (BeiGene) (ONC)
- Sponsor type
- Industry
- First posted
- Oct 10, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to measure the safety, preliminary antitumor activity, pharmacokinetics, and pharmacodynamics with tacabrutideg in combination with other agents in participants with relapsed or refractory (R/R) B-cell malignancies. This study is structured as a master protocol with separate substudies. This study currently includes four substudies, and more substudies may be added as other combination agents are identified.
Conditions
- B-cell Malignancy
- Relapsed Cancer
- Refractory Cancer
- B-cell Lymphoma
Interventions
TacabrutidegDrug
Administered orally
SonrotoclaxDrug
Administered orally
ZanubrutinibDrug
Administered orally
MosunetuzumabDrug
Administered subcutaneously
GlofitamabDrug
Administered intravenously
ObinutuzumabDrug
Administered intravenously
Primary outcomes
What the sponsor says the trial is designed to measure.
- Substudy 1 Part 1a: Number of participants with dose-limiting toxicities (DLTs), treatment-emergent adverse events, treatment-related adverse events, and serious adverse eventsTime frame: From the first dose of study drug(s) to 30 days after the last dose; up to approximately 2 years
- Substudy 1 Part 1b: Number of participants with treatment-emergent adverse events, treatment-related adverse events, and serious adverse eventsTime frame: From the first dose of study drug(s) to 30 days after the last dose; up to approximately 2 years
- Substudy 2 Part 1a: Number of participants with dose-limiting toxicities (DLTs), treatment-emergent adverse events, treatment-related adverse events, and serious adverse eventsTime frame: From the first dose of study drug(s) to 30 days after the last dose; up to approximately 2 years
- Substudy 2 Part 1b: Number of participants with treatment-emergent adverse events, treatment-related adverse events, and serious adverse eventsTime frame: From the first dose of study drug(s) to 30 days after the last dose; up to approximately 2 years
- Substudy 3 Part 1a: Number of participants with dose-limiting toxicities (DLTs), treatment-emergent adverse events, treatment-related adverse events, and serious adverse eventsTime frame: From the first dose of study drug(s) to 30 days after the last dose; up to approximately 2 years
- Substudy 3 Part 1b: Number of participants with treatment-emergent adverse events, treatment-related adverse events, and serious adverse eventsTime frame: From the first dose of study drug(s) to 30 days after the last dose; up to approximately 2 years]
- Substudy 4 Part 1a: Number of participants with dose-limiting toxicities (DLTs), treatment-emergent adverse events, treatment-related adverse events, and serious adverse eventsTime frame: From the first dose of study drug(s) to 30 days after the last dose; up to approximately 2 years
- Substudy 4 Part 1b: Number of participants with treatment-emergent adverse events, treatment-related adverse events, and serious adverse eventsTime frame: From the first dose of study drug(s) to 30 days after the last dose; up to approximately 2 years
Locations
49 sites in 8 countries. Site status is shown where the registry gives one.
Mayo Clinic Phoenix
Phoenix, Arizona · Recruiting
University of Southern California Norris Comprehensive
Los Angeles, California · Recruiting
Mayo Clinic Jacksonville
Jacksonville, Florida · Recruiting
Moffitt Cancer Center
Tampa, Florida · Recruiting
The University of Kansas Cancer Center
Westwood, Kansas · Recruiting
Mayo Clinic Rochester
Rochester, Minnesota · Recruiting
Washington University School of Medicine
St Louis, Missouri · Recruiting
Icahn School of Medicine At Mount Sinai
New York, New York · Recruiting
Columbia University Medical Center
New York, New York · Recruiting
Weill Cornell Medical College Newyork Presbyterian Hospital
New York, New York · Recruiting
Memorial Sloan Kettering Cancer Center Mskcc
New York, New York · Recruiting
University of Rochester
Rochester, New York · Recruiting
Fox Chase Cancer Center
Philadelphia, Pennsylvania · Recruiting
The University of Texas Md Anderson Cancer Center
Houston, Texas · Recruiting
Huntsman Cancer Institute
Salt Lake City, Utah · Recruiting
University of Wisconsin
Madison, Wisconsin · Recruiting
Medical College of Wisconsin
Milwaukee, Wisconsin · Recruiting
St George Hospital
Kogarah, New South Wales, Australia · Recruiting
Mater Cancer Care Centre
South Brisbane, Queensland, Australia · Recruiting
Monash Health
Clayton, Victoria, Australia · Recruiting
Peter Maccallum Cancer Centre
Melbourne, Victoria, Australia · Recruiting
The Alfred Hospital
Melbourne, Victoria, Australia · Recruiting
Linear Clinical Research
Nedlands, Western Australia, Australia · Recruiting
Hospital Sirio Libanes Brasilia
Brasília, Brazil · Recruiting
Ensino E Terapia de Inovacao Clinica Amo Etica
Salvador, Brazil · Recruiting
Fundacao Faculdade Regional de Medicina de Sao Jose Do Rio Preto
São José do Rio Preto, Brazil · Recruiting
Sociedade Beneficente Israelita Brasileira Hospital Albert Einstein
São Paulo, Brazil · Recruiting
Fujian Medical University Union Hospital
Fuzhou, Fujian, China · Recruiting
Sun Yat Sen University Cancer Center
Guangzhou, Guangdong, China · Recruiting
The First Affiliated Hospital of Soochow University
Suzhou, Jiangsu, China · Recruiting
The First Affiliated Hospital, Zhejiang University School of Medicinechengzhan
Hangzhou, Zhejiang, China · Recruiting
The First Affiliated Hospital of Wenzhou Medical University
Wenzhou, Zhejiang, China · Recruiting
Universitatsklinikum Carl Gustav Carus An Der Technischen Universitat Dresden
Dresden, Germany · Recruiting
Universitatsklinikum Jena Klinik Fur Innere Medizin Ii
Jena, Germany · Recruiting
Universitatsklinikum Schleswig Holstein Campus Kiel
Kiel, Germany · Recruiting
Medizinische Universitaetsklinik
Tübingen, Germany · Recruiting
Universitaetsklinikum Ulm
Ulm, Germany · Recruiting
Azienda Ospedaliera Universitaria Policlinico Santorsola Malpighi
Bologna, Italy · Recruiting
Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda
Milan, Italy · Recruiting
Istituto Nazionale Tumori Fondazione G Pascale
Naples, Italy · Recruiting
Showing 40 of 49 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.